Search results
GSK plc (NYSE:GSK) Receives $47.00 Average Target Price from Brokerages
ETF DAILY NEWS· 8 hours agoShares of GSK plc (NYSE:GSK – Get Free Report) have received an average rating of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat ...
GSK plc (NYSE:GSK) Shares Acquired by First Hawaiian Bank
ETF DAILY NEWS· 4 days agoFirst Hawaiian Bank boosted its holdings in GSK plc (NYSE:GSK – Free Report) by 3.3% in the first quarter, according to the company in its most recent Form ...
9,154 Shares in GSK plc (NYSE:GSK) Bought by Virtu Financial LLC
ETF DAILY NEWS· 4 days agoVirtu Financial LLC acquired a new position in shares of GSK plc (NYSE:GSK – Free Report) in the fourth quarter, according to its most recent 13F filing ...
Cwm LLC Cuts Stock Holdings in GSK plc (NYSE:GSK)
ETF DAILY NEWS· 4 days agoCwm LLC trimmed its stake in shares of GSK plc (NYSE:GSK – Free Report) by 7.2% in the 1st quarter, according to its most recent disclosure with the SEC ...
NBC Securities Inc. Has $1.43 Million Stock Holdings in GSK plc (NYSE:GSK)
ETF DAILY NEWS· 4 days agoNBC Securities Inc. trimmed its position in GSK plc (NYSE:GSK – Free Report) by 1.7% in the first quarter, according to the company in its most recent Form ...
Leo Wealth LLC Purchases New Shares in GSK plc (NYSE:GSK)
ETF DAILY NEWS· 6 days agoLeo Wealth LLC purchased a new stake in GSK plc (NYSE:GSK – Free Report) during the 4th quarter, according to the company in its most recent filing with ...
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market...
Morningstar· 4 days agoFN Media Group News Commentary - The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. Unlike traditional therapeutic ...
Gilead's twice-a-year HIV PrEP drug delivers stunning results in late-stage study - San Francisco...
The Business Journals· 3 days agoInjected only twice a year, an HIV PrEP drug developed by Gilead Sciences Inc. showed zero...
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
Zacks via Yahoo Finance· 3 days agoGilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool...
Industry groups back drugmakers' appeal in Zantac cancer lawsuits
Reuters· 4 days ago, opens new tab and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued...